Iteos Home

Press Releases

Home / Investors / iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

Press Release Details

iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

April 20, 2020
PDF Version

Gosselies, Belgium and Cambridge, MA – April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.    

 

The abstract and video presentation details are as follows:

Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152)

Session: Phase I Clinical Trials
Abstract #: 10228
Authors: Laurence Buisseret, et al.

 

The video presentation and full abstract will be available on the AACR conference website from 9:00 AM ET on Monday, April 27th.

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics SA

info@iteostherapeutics.com

Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

Sarah McCabe and Zofia Mita

Stern Investor Relations, Inc.

+ 1 212 362 1200

iTeos@sternir.com

For investors

scientist picking up a petri dish

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.